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10 Oral PresentationsPeripheral blood stem cells (PBSC) have been increasingly used
in the matched unrelated donor (MUD) transplant setting, but
the impact of CD341 cell dose on outcomes in this setting have
not been well characterized. We analyzed a consecutive case-series
of 181 patients who underwentMUD-PBSC transplantation at City
of Hope from August 2000 to December 2004. Eighty-three pa-
tients were conditioned with a full-intensity regimen (TBI-Cy:
46, TBI-VP16: 28, Bu-Cy: 9) and 98 received a reduced-intensity
regimen (Flu-Mel: 97, Flu-Bu: 1). The two-year overall survival
(OS), disease-free survival (DFS), relapse, and 100-day transplant-
related mortality (TRM) probabilities were 52%64%, 47%64%,
29%64%, and 156 3% respectively. There was a highly significant
correlation betweenCD341 cell dose infused and absolute lympho-
cyte count on day 30 post-transplant (r 5 0.378, p\ 0.0001). By
univariate analysis, a CD341 cell dose $4.2  106/kg (above the
lowest quartile: p25) was associated with significantly lower relapse
risk (HR5 0.67; p5 0.013), with a trend toward improved disease-
free survival (HR 5 0.84; p 5 0.12) but not overall survival (HR 5
0.91; p5 0.46). There was no significant association between higher
CD341 cell dose and TRM or acute/chronic GVHD. By multivar-
iate analysis, cellular composition of the PBSC grafts remained sig-
nificant in influencing transplant outcomes (Table 1). Further
subset analysis of low risk group (n 5 35) versus high-risk disease
(n5 146) showed that the CD341 dose$ p25 was significantly as-
sociated with reduced relapse in high-risk disease (p 5 0.015),
whereas the p-value was not significant in low-risk disease (p 5
0.5). Among 18 patients with an iKIRL mismatch in the GVH di-
rection, the log-rank p-value for comparing\ p25 of CD341 cell
dose versus those who received higher doses was p\ 0.0001 with
respect to time to relapse. This is in contrast with p5 0.041 among
the others. We also performed a stratified analysis in patients lack-
ing iKIRL (n 5 56) versus not (n 5 125). When stratified by
CD341 cell dose, time-to-relapse was not significant among the pa-
tients who did not lack iKIRL but was significant in patients lacking
iKIRL (p 5 0.0030). In summary, we demonstrate that the higher
CD341 cell dose reduces relapse in MUD-PBSCT, in particular,
for high-risk diseases. The data also suggest that the protective ef-
fect of higher CD341 cell dose may be linked to an NK cell-medi-
ated GVL effect.Table 1.
HR p-valuesOS
10/10 HLA match
(baseline) vs. others2.23 (95%CI: 1.46–3.43) 0.0002Lymphocyte dose in
the graft (continuous)0.20 (95%CI: 0.05–0.64) 0.005MNC dose in the
graft: p25 (baseline)
vs. others1.34 (95%CI: 1.01–1.82) 0.04DFS
10/10 HLA match
(baseline) vs. others1.91 (95%CI: 1.28–2.87) 0.001Lymphocyte dose in
the graft (continuous)0.35 (95%CI: 0.14–0.81) 0.01Good risk disease
(baseline) vs. others1.73 (95%CI: 1.01–3.17) 0.04Relapse
CD341 quartile: p25
(baseline) vs. others0.64 (95%CI: 0.47–0.88) 0.01Recipient age
(continuous)1.02 (95%CI: 1.00–1.05) 0.02TRM
10/10 HLA match
(baseline) vs. others2.46 (95%CI: 1.44–4.30) 0.001Full-intensity
(baseline) vs.
reduced-intensity
conditioning1.76 (95%CI: 1.03–3.10) 0.04MNC: mononuclear cell.21
PREPARATION OF HIGHLY PURIFIED REGULATORY T CELLS FOR CLIN-
ICAL APPLICATIONS
Sheehan, K.1, Armstrong, R.1, Tudisco, C.1, Hou, J.-Z.2, Negrin, R.1.
1Stanford University Medical Center, Stanford, CA; 2University of
Pittsburgh Medical Center, Pittsburgh, PA.
Naturally occurring regulatory T cells (Treg) may limit or pre-
vent the immune mediated morbidity associated with allogeneic
transplants. The administration of Treg along with specified doses
of conventional T cells (Tcon) has been proposed as an alternative
to current T cell reduction strategies. This approach may provide
patients with immune protection and graft-versus-tumor activity
during post-transplant immune reconstitution while minimizing
the risk of severe graft-versus-host responses when the donor and
recipient are mismatched.
In order to establish the optimal dose of Treg to be administered
with Tcon, highly purified Treg are required. Isolation of Tregs for
clinical application is complicated by the lack of an exclusive surface
marker suitable for selection and the relatively rare representation
(\1%) of the cells in peripheral blood. Treg are characterized by
surface expression of CD4, CD25, CTLA-4, and GITR among
other markers and by intracellular expression of the transcriptional
factor FoxP3.
We conducted a feasibility study of a cell selection strategy that
combines immunomagnetic enrichment of CD251 cells with high
flow cytometric speed cell sorting of CD41CD25brightCD127dim
cells. System operations took into consideration selection effi-
ciency, effect on cell viability and functionality as well as the
risk of contamination both from external sources and product
cross-contamination. Using this approach, we have obtained cells
that are .95% FoxP31 by intracellular staining and showing ti-
tratable suppression in MLR assays. Recovery of the target cell
population on the Influx cell sorter was .90% at 20,000 events
per second and without detectable microbial contamination. In ad-
dition, more than 100  106 FoxP31 Tregs were routinely ob-
tained from individual G-CSF mobilized donor apheresis
collections.GVH/GVL22
DISCOVERY OF LEUKEMIA ASSOCIATED MINOR HISTOCOMPATIBILITY
ANTIGENS USING CD81 T CELL CLONES ISOLATED BY PRIMARY IN VI-
TRO STIMULATION OF NAI¨VE T CELLS
Bleakley, M.1, Nishida, T.1, Otterud, B.2, Riddell, S.1. 1Fred Hutchinson
Cancer Research Center, Seattle, WA; 2University of Utah, Salt Lake
City, UT.
Allogeneic hematopoietic stem cell transplantation (HCT) is cu-
rative for many patients with leukemia in part due to a graft versus
leukemia (GVL) effect mediated by donor T cells specific for recip-
ient minor histocompatibility antigens (miH) on leukemic cells.
Unfortunately, the GVL effect fails to completely eradicate leu-
kemia in some patients, and additional strategies for preventing
and treating post HCT relapse are required. Immunotherapy tar-
geting miH selectively expressed on hematopoietic cells, includ-
ing leukemia, could be used to augment the GVL effect
without inducing GVHD but too few human miH have been mo-
lecularly characterized for this approach to be broadly applied.
The identification of additional leukemia associated miH is essen-
tial. We developed a new strategy that employs primary in vitro
stimulation of donor naı¨ve CD81 T cells (TN) with recipient
APC in microcultures, allowing generation of a broad repertoire
of miH specific CTL for gene discovery. Using this approach,
.100 miH specific CD81 CTL lines were derived from 19
HLA identical sibling recipient-donor pairs and further charac-
terized using a panel of target cells from unrelated individuals
to determine the HLA restricting allele and population frequency
of the miH. CTL directed against multiple distinct miH were
Oral Presentations 11isolated from the majority of donors and 1/3 of these recognized
a miH that was presented by a prevalent HLA allele and ex-
pressed on hematopoietic cells but not dermal fibroblasts. CTL
clones were isolated from these T cell lines and the polymorphic
genes encoding the novel miH were mapped by assessing recog-
nition of CEPH LCL transfected with the HLA restricting allele
and performing genetic linkage analysis and/or by cDNA library
screening. As most miH result from single nucleotide polymor-
phisms (SNP), we used the NCBI dbSNP database to access
SNP genotypes on a subset of the HapMap CEPH family mem-
bers and correlated the genotype with the miH phenotype to de-
rive a short list of candidate SNPs for the miH. We have
identified genes encoding five novel miHs so far and the tissue
expression of these genes is currently being evaluated. At least
one of the miH appears to be selectively expressed on hematopoi-
etic cells including leukemic stem cells and serves as a target for
effective T cell therapy of human leukemia in NOD/SCID mice.
Generation of miH specific CTL by primary in vitro stimulation
is an effective tool for accelerating the discovery of leukemia
associated miH.23
A NOVEL METHOD TO REDUCE RATES OF EXTENSIVE CHRONIC GVHD
(cGvHD) WITHOUT INCREASED RELAPSE FOR CORD BLOOD TRANS-
PLANT
Chow, R.1,8, Wang, B.1, Rosenthal, J.2, Nademanee, A.2, Karanes, C.2,
Jaing, T.-H.3, Graham, M.4, Delaney, C.5, Gjertson, D.6, Petz, L.1,6,
Forman, S.2, Kurtzberg, J.7. 1Stemcyte International Cord Blood Center,
Arcadia, CA; 2City of Hope National Medical Center, Duarte, CA;
3Chang Gung Children’s Hospital, Linkou, Taiwan; 4University of Ari-
zona Medical Center, Tucson, AZ; 5Fred Hutchinson Cancer Research
Center, Seattle, WA; 6UCLA School of Public Health, Los Angeles,
CA; 7Duke University, Durham, NC; 8StemCyte Taiwan National
Cord Blood Center, Linkou, Taiwan.
Post-thawwashing of frozenCB prior to transplantation is widely
practiced to remove DMSO, red cell debris and free hemoglobin,
however, washing a red cell containing product may result in cell
loss. We analyzed outcomes of engraftment, survival, relapse and
GvHD in 299 patients transplanted with plasma depleted but not
red cell reduced (PD) CB where 154 were washed (W) and 145ANC 500
& Plt 20 K
100 Day
TRM
1 & 3
Yr OS
1 &
3 Yr DFS
1 Yr
Relapse
Grade
II-IV/III-IV
aGvHD
Limited/
Extensive
cGvHD
Overall 88 ± 4/69 ± 4 17 ± 2 61 ± 3/56 ± 3 51 ± 3/39 ± 5 23 ± 3 35/14 20/11
W 87 ± 5/64 ± 5 17 ± 3 54 ± 4/48 ± 4 43 ± 5/30 ± 6 27 ± 5 36/15 9/17
NW 91 ± 6/76 ± 6 16 ± 3 69 ± 4/67 ± 4 60 ± 5/57 ± 5 20 ± 4 36/14 36/1
P value 0.002/0.001 0.05 0.02 0.05 0.29 0.93/0.80 \0.0001/
0.0005
MVAdjusted ANC 500
& Plt 20 K
TRM OS DFS Relapse Grade
II-IV/III-IV
aGvHD
Limited/
Extensive
cGvHD
Cox RR (W
Reference)
1.51/1.70 0.67 0.71 0.74 0.76 N/A 3.88/0.05
P value
(W vs.
NW)
0.002/0.001 0.11 0.09 0.11 0.34 N/A \0.001/
0.004
Matched Pair
Analysis
ANC 500
& Plt 20 K
TRM OS DFS Relapse Grade
II-IV/III-IV
aGvHD
Limited/
Extensive
cGvHD
P value
(W vs.
NW)
0.008/0.0002 0.53 0.32 0.22 0.19 0.98/0.44 0.02/0.001
All results are in % except for p-values & where indicated. Engraft-
ment presented as cumulative incidence. TRM, OS, DFS and
relapse rate estimated by Kaplan-Meier methods.were directly infused – (non-washed or NW). 207 (69%) of the
299 patients had malignant diagnosis. The two groups were com-
parable for patient, disease and graft characteristics except for
a higher % of Asian patients in the NW group in contrast to
a higher % of Caucasian/Hispanic patients, higher % of US
transplant centers and higher number of malignant diagnoses
for the W group. Nucleated cell recovery after thawing, as re-
ported by transplant centers, was higher for NW (median 85%
vs. 79%, p 5 0.003). The NW group had higher cumulative in-
cidences of and faster neutrophil (ANC500) and platelet engraft-
ment (Plt 20K and 50K) than the W group. No difference was
seen for acute GvHD (aGvHD); however, the NW group had
significantly lower rates of extensive cGvHD and higher rates of
limited cGvHD (p 5 0.0005 and \0.0001). Relapse rates were
similar between W and NW. Multivariate analysis and matched
pair analysis between W versus NW confirm these observations.
In univariate analysis, overall survival (OS) and disease-free sur-
vival (DFS) at 1 and 3 years were significantly higher for the
NW group. This retrospective analysis represents the largest se-
ries comparing different thaw methods for PD CB and is the first
to demonstrate a potential association of no post-thaw wash with
significant decrease in extensive cGvHD rate without concomi-
tant increase in relapse rate. These improvements may contribute
to the apparently better survival for the NW group. Prospective
trials which may include infusion of wash supernatants into
patients are necessary to confirm and better understand these
observations.24
CRITICAL ROLE FOR DONOR ANTIGEN-PRESENTING CELL SECRETION
OF INTERLEUKIN 23 IN THE PATHOPHYSIOLOGY OF GRAFT VERSUS
HOST DISEASE OF THE COLON
Das, R.1, Komorowski, R.1,Ghilardi,N.2,Hessner,M.1,Drobyski,W.R.3.
1Medical College of Wisconsin; 2Genentech, South San Francisco, CA;
3Medical College of Wisconsin, Milwaukee, WI.
The initiation of graft versus host disease (GVHD) is dependent
upon donor T cell recognition of host alloantigens presented within
the context of host antigen presenting cells (APCs). Thereafter, host
APCs are replaced by donor APCs, however the role of donor APCs
in the propagation of GVHD remains largely unknown. Recently,
interleukin 23 has been identified as a cytokine that is secreted ex-
clusively by APCs (i.e. dendritic cells and macrophages) and has
been shown to play a major role in both local and systemic inflam-
matory responses. The purpose of these studies, therefore, was to
address this question by determining whether secretion of IL-23
by donor APCs played a role in either the local or systemic manifes-
tations of GVHD.Transplantation of bonemarrow and spleen cells
from IL-23 deficient C57BL/6 (B6)(H-2b) donors into lethally irra-
diated MHC-incompatible Balb/c (H-2d) or FVB (H-2q) mice re-
sulted in significantly reduced weight loss and proinflammatory
serum cytokine production, as well as improved splenic and thymic
reconstitution, when compared to animals transplanted with mar-
row grafts from normal B6 mice. Histological examination of
GVHD target tissues revealed that the reduction in the systemic
manifestations of GVHDwas accompanied by significantly reduced
pathological damage in the colon without any corresponding reduc-
tion in pathological scores in either lung or liver. To further under-
stand the role of IL-23 in colonic GVHD pathology, we examined
local proinflammatory cytokine production in colonic explant tis-
sues from both cohorts of mice. Transplantation with IL-23 defi-
cient marrow grafts was associated with significantly decreased
levels of IL-23, IFN-g, G-CSF, TNF-a, IL-1b and IL-6 in colonic
explant supernatants. Neither IL-12 nor IL-17 levels were altered
by the absence of donor-derived IL-23, providing evidence that
the proinflammatory effects of IL-23 in the colon occur indepen-
dently of these cytokines. Notably, levels of lipopolysaccharide
(LPS) which has been shown to have a vital role in the pathophysi-
ology of gut GVHDwere significantly decreased in both the serum
and in colonic explants from these animals. These data demonstrate
that IL-23 plays a unique role in the pathophysiology of GVHD of
the colon and is a proximate mediator in the cytokine cascade in-
duced by LPS translocation from the colon into the serum. These
